menu
    • menu
    [{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Amgen Inc"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azathioprine","moa":"||IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Azathioprine Sodium USP

    Menu

    Azathioprine Sodium USP

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            AGGSpend
                            Not Confirmed

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Satralizumab,Azathioprine,Mycophenolate Mofetil

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Roche’s Enspryng Leads Latest CHMP Recommendations

                            Details : Leading those recommendations is Roche’s Enspryng (satralizumab), which received a positive opinion for the treatment of the rare autoimmune disease neuromyelitis optica spectrum disorders (NMOSD).

                            Product Name : Enspryng

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 23, 2021

                            Lead Product(s) : Satralizumab,Azathioprine,Mycophenolate Mofetil

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amgen Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avacopan,Azathioprine,Rituximab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Ass...

                            Details : The NDA included data from the global, Phase III ADVOCATE trial, which demonstrated statistical superiority in sustaining remission at 52 weeks in the avacopan group compared to the prednisone group.

                            Product Name : Tavneos

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 17, 2020

                            Lead Product(s) : Avacopan,Azathioprine,Rituximab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amgen Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avacopan,Azathioprine,Rituximab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Data from ADVOCATE Phase III Trial...

                            Details : The study showed that avacopan was as effective as prednisone therapy in bringing patients into remission by 26 weeks, and superior to prednisone for sustained remission after 52 weeks.

                            Product Name : Tavneos

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 11, 2020

                            Lead Product(s) : Avacopan,Azathioprine,Rituximab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CSL

                            Australia arrow
                            AGGSpend
                            Not Confirmed

                            CSL

                            Australia arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avacopan,Azathioprine,Rituximab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VFMCRP and ChemoCentryx Announce European Medicines Agency has Accepted to Review the Marketing Authorization ...

                            Details : If approved, avacopan would be the first orally administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

                            Product Name : Tavneos

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 11, 2020

                            Lead Product(s) : Avacopan,Azathioprine,Rituximab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth